NANOBIOTIX : Nanobiotix expands its clinical development in Head and Neck cancer and Immuno-Oncology ; new clinical data to be ...
NANOBIOTIX EXPANDS ITS CLINICAL DEVELOPMENT IN HEAD AND NECK CANCER AND IMMUNO-ONCOLOGY NEW CLINICAL DATA TO BE PRESENTED AT ASCO Paris, France and Cambridge, Massachusetts, April 4, 2017 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late …